Skip to Content

DexCom Inc DXCM

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Stewardship

PREMIUM

Dexcom Posts Strong Second Quarter; We've Raised our Fair Value Estimate

Debbie S. Wang Senior Equity Analyst

Analyst Note

| Debbie S. Wang |

No-moat Dexcom’s strong second-quarter performance is a testament to the larger secular trend of diabetes patients embracing continuous glucose monitors thanks to a spurt of meaningful innovation. We’ve raised our fair value estimate to $207 per share, up from $185, after adjusting our estimates for sensor growth upwards for 2020. Nonetheless, shares remain overvalued, from our perspective. We’d originally projected 15% topline growth for the full year on the assumption that the pandemic would significantly disrupt new patients from starting on the G6 CGM. We now think we substantially undershot, based on how quickly Dexcom saw new patients return through the second quarter, and have increased our projection for 28% revenue growth this year.  Dexcom saw 20% to 25% declines in new patient starts in late March and during April when shelter-in-place orders descended. However, this pipeline of new patients had recovered fairly well by end of June. Considering the on-going flareups of COVID-19 in different areas, we now expect positive growth in new patients, albeit at lower levels than usually seen as the pandemic continues to damp normal consumer activity.

Read Full Analysis

Company Profile

Business Description

Dexcom designs and commercializes continuous glucose monitoring (CGM) systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company sells three different pieces of equipment, a sensor, a transmitter, and a receiver.

Contact
6340 Sequence Drive
San Diego, CA, 92121
T +1 858 200-0200
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings Jun 30, 2020
Fiscal Year End Dec 31, 2020
Stock Type Speculative Growth
Employees 5,200